Nawaloka Hospitals PLC (COSE:NHL.N0000)
Sri Lanka · Delayed Price · Currency is LKR 0.00
0.00 (0.00%)
Price not available due to exchange restrictions
Nawaloka Hospitals Financials Overview
Financials in millions LKR. Fiscal year is April - March.
Millions LKR. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Revenue Revenue Growth | 12,621 | 11,013 | 10,379 | 9,305 | 15,302 | 11,828 |
Revenue Growth | 17.33% | 6.10% | 11.54% | -39.19% | 29.38% | 30.90% |
Gross Profit Gross Profit Growth | 6,934 | 5,878 | 5,617 | 4,635 | 7,841 | 5,542 |
Operating Income Operating Income Growth | 1,549 | 1,003 | 1,025 | -73.46 | 1,914 | 1,501 |
Net Income Net Income Growth | 1,019 | 56.38 | -304.75 | -2,438 | -96.59 | 501.26 |
Earnings Per Share EPS Growth | 0.71 | 0.04 | -0.22 | -1.73 | -0.07 | 0.36 |
EPS Growth | - | - | - | - | - | 3456.31% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Hospital Services Hospital Services Growth | 4,805 | 4,655 | 3,739 | 5,197 | 2,892 |
Pharmaceutical Pharmaceutical Growth | 2,954 | 2,704 | 2,700 | 2,491 | 2,010 |
Laboratories Laboratories Growth | 2,103 | 2,031 | 1,983 | 6,756 | 6,230 |
Radiology Services Radiology Services Growth | 1,151 | 988.61 | 883.72 | 857.56 | 695.96 |
Unallocated/Eliminations Unallocated/Eliminations Growth | -0.09 | -0.26 | -0.79 | 0.56 | -0.01 |
Total Total Growth | 11,013 | 10,379 | 9,305 | 15,302 | 11,828 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Investments Cash & Investments Growth | 664.87 | 619.15 | 470.99 | 290.02 | 802.87 | 1,190 |
Total Debt Total Debt Growth | 8,488 | 7,784 | 7,505 | 8,142 | 9,658 | 11,730 |
Net Cash (Debt) Net Cash Growth | -7,823 | -7,165 | -7,034 | -7,852 | -8,855 | -10,540 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -5.45 | -5.08 | -4.99 | -5.57 | -6.28 | -7.48 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 1,485 | 1,133 | 2,124 | 2,885 | 2,375 | 524.09 |
Capital Expenditures CapEx Growth | -1,944 | -340.65 | -76.83 | -133.06 | -1,116 | -589.45 |
Free Cash Flow Free Cash Flow Growth | -459.03 | 792.79 | 2,047 | 2,752 | 1,259 | -65.36 |
Free Cash Flow Growth | - | -61.28% | -25.61% | 118.61% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Gross Margin | 54.94% | 53.38% | 54.12% | 49.81% | 51.24% | 46.86% |
Operating Margin | 12.27% | 9.11% | 9.87% | -0.79% | 12.51% | 12.69% |
Pretax Margin | 11.33% | 3.06% | -2.38% | -20.53% | 2.98% | 2.94% |
Profit Margin | 8.07% | 0.51% | -2.94% | -26.21% | -0.63% | 4.24% |
FCF Margin | -3.64% | 7.20% | 19.73% | 29.58% | 8.23% | -0.55% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 10, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
PE Ratio | 19.02 | 132.50 | - | - | - | 13.78 |
P/FCF Ratio | - | 9.42 | 2.69 | 2.92 | 7.28 | - |
PS Ratio | 1.51 | 0.68 | 0.53 | 0.86 | 0.60 | 0.58 |